Tivic Health®Systems, Inc. announced that enrollment in its pilot clinical study of a proprietary approach to non-invasive vagus nerve stimulation (VNS) has been completed. VNS is a growing market that is part of the $8.3 Billion global neurostimulation market, which has a projected CAGR of 12.2%, according to Global Market Insights. Implanted VNS is currently used in the treatment of various neurologic and psychiatric disorders and is being tested in systemic inflammatory diseases.

Tivic is testing a proprietary approach to more precisely influence vagus nerve signals, while enhancing effectiveness and safety with a non-invasive treatment. The pilot study utilized a new neurostimulation approach with 20 individuals during which the data collection and analysis were performed by researchers at The Feinstein Institutes for Medical Research. This work aims to provide more precise targeting strategies for VNS and more control over the types of physiologic effects that result from stimulation.